Trial abstract · §3
ECNO-PH3-CN-T2D — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in glycated haemoglobin from baseline to week 52 | no result held by the Institute | Not rated |
| The Institute publishes no effect estimate for a trial whose report it does not hold. | ||
§3.2Harms as reported
Table 5. Adverse events for Ecnoglutide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | — | — | Class-typical gastrointestinal profile reported without full tabulation |
| Vomiting | — | — | Reported |
| Discontinuation for adverse events | — | — | Not fully tabulated in available sources |
Compound Evidence Institute · CEI-TR-0067/3 · https://compoundevidence.com/trials/ecno-ph3-cn-t2d/results/ · retrieved 30 July 2026